Based on recent deals, an effective cancer drug against one solid tumor type is worth about $5B-10B. We all know how much Imbruvica was sold for. Kevetrin has the potential to treat both solid and blood cancers. That's why I was disappointed when the AML trial was put on hold due to lack of funding.

I agree that if the K-OC trial is successful, CTIX should have no problem finding partners for other indications.

Quote:

---

Likely it will get to market for ovarian cancer first, but when CTIX secures a partnership and funding from the other drugs, they may be able to open up several other pathways for K in parallel with the ovarian cancer indication.

---